Morgan Bardall
Psychiatric/Mental Health · Hazlet, NJNPI 1376130591
Payments from drug & device makers
Across 217 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$221
- Neurocrine Biosciences, Inc.$163
- Sunovion Pharmaceuticals Inc.$134
- Axsome Therapeutics, Inc.$125
- Takeda Pharmaceuticals U.S.A., Inc.$125
- plus $495 from 10 others
What the payments were for
- Food & beverage$3,322100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $2,059 |
| Johnson & Johnson | 11 | $221 |
| Neurocrine Biosciences, Inc. | 3 | $163 |
| Sunovion Pharmaceuticals Inc. | 10 | $134 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $125 |
| Alkermes, Inc. | 6 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $70 |
| Supernus Pharmaceuticals, Inc. | 5 | $68 |
| Lundbeck LLC | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 4 | $56 |
| Indivior Inc. | 4 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $27 |
| Corium, LLC | 2 | $26 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$588
- INGREZZA$136
- SUNOSI$125
- INVEGA SUSTENNA$110
How this compares
$3,322 in reported general payments places this provider in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 21 | $32,157 |
| CymbaltaDuloxetine Hcl | 12 | $6,258 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $1,961 |
| Risperidone | 31 | $1,754 |
| Lamotrigine ErLamotrigine | 13 | $1,641 |
| Bupropion XlBupropion Hcl | 56 | $777 |
| Fluoxetine Hcl | 66 | $714 |
| Olanzapine | 46 | $529 |
| Benztropine Mesylate | 42 | $528 |
| Duloxetine Hcl | 15 | $470 |
| Lamotrigine | 56 | $446 |
| Quetiapine Fumarate | 34 | $350 |
| Naltrexone Hcl | 11 | $347 |
| Trazodone Hcl | 43 | $310 |
| Buspirone Hcl | 38 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $56 | $32,15721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Hazlet
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.